In the surgical setting, fibrinolysis can be a serious complication of anaphylaxis. We present four cases of anaphylaxis that were associated with fibrinolysis during anaesthesia, and the use of the thrombelastograph to demonstrate this haemostatic defect and its correction using tranexamic acid.
A wide variety of substances used during anaesthesia can cause anaphylaxis following intravenous administration, including intravenous induction agents, muscle relaxants, opioids, antibiotics, colloidal solutions and blood products. The respiratory, cardiovascular and cutaneous signs of anaphylaxis and their treatment are well understood. There is however, a paucity of published reports of fibrinolysis occurring during anaphylaxis 1 . In this paper we present four cases which occurred in our department over a twelve-month period in which anaphylaxis with associated fibrinolysis was successfully detected using thrombelastography (TEG) and reversed with tranexamic acid. The pathophysiological effects of anaphylaxis and anaphylactoid reactions on coagulation are discussed, as are the clinical implications of using TEG and tranexamic acid for early detection and treatment of these effects.
CASE REPORTS Case 1
A 35-year-old female presented for surgery with a posterior communicating artery aneurysm. She was otherwise healthy, on no regular medications and had no history of drug allergy. Preoperative blood tests are shown in Table 1 .
The patient received premedication of ranitidine, temazepam and metoclopramide. Anaesthesia was induced with midazolam, propofol, rocuronium and remifentanil, and maintained with sevoflurane in 50% oxygen and a remifentanil infusion. Thirty minutes later a second dose of rocuronium was given followed by cephazolin. Within five minutes her arterial systolic blood pressure dropped from 90 to 50 mmHg and heart rate increased to 110/min. Escalating doses of metaraminol (0.5 mg, 1 mg, 2 mg, and 5 mg) had no effect. Widespread erythema was noted but there was no evidence of bronchospasm. Anaphylaxis was diagnosed and adrenaline boluses were given to a total of 0.5 mg. The patient also received crystalloid and colloid fluid resuscitation, dexamethasone, cyclizine and ranitidine.
Blood was taken for full blood count, coagulation and tryptase (Table 1) and TEG, which showed severe fibrinolysis ( Figure 1 ). In view of the severe fibrinolysis on thrombelastography and the urgency of the surgery, it was decided to administer tranexamic acid (200 mg) and two units of fresh frozen plasma in an attempt to correct the patient's coagulation status. The TEG was repeated, and showed complete resolution of the coagulopathy (Figure 2 ). Surgery and postoperative recovery were uneventful. The patient did not attend our Allergy Clinic six weeks postoperatively.
Case 2
A 68-year-old female presented for the elective resection of a solitary liver metastasis. She had a past history of Duke's grade C cancer of the transverse colon, resected one year previously. The patient had been taking ibuprofen and had no known drug allergies. Preoperative blood tests are shown in Table 1 . Anaesthesia was induced using midazolam, fentanyl, propofol and vecuronium, and maintained with isoflurane in 50% oxygen. A thoracic epidural was inserted preoperatively and 10 ml 0.5% bupivacaine and 150 µg fentanyl was administered in divided doses after induction. A dopamine infusion (20 mg/h) was initiated in order to counteract the arterial blood pressure drop (158/82 to 80/50 mmHg) caused by induction agents and epidural administration. The case continued with the patient's mean arterial pressures maintained at 70 to 80 mmHg.
Two-and-a-half hours after induction the patient suddenly developed hypotension with systolic pressures less than 50 mmHg during the infusion of a second unit of succinylated gelatin solution 4% (Gelofusin ® : Braun, Switzerland). There was no associated tachycardia. Widespread cutaneous flushing was noted but there was no evidence of bronchospasm. Anaphylaxis was diagnosed and she was given adrenaline 150 µg and hydrocortisone 200 mg with rapid effect.
Blood tests for coagulation, tryptase and TEG were taken (Table 1) . Tranexamic acid 1 g was given to the patient as the TEG demonstrated fibrinolysis and there was oozing from the cut surface of the patient's liver. A repeat TEG one hour later showed the fibrinolysis had resolved, although the coagulation tests still showed some prolongation (Table 1 ). Clinically the patient was "dry" at closing of the wound. Six weeks postoperatively at our Allergy Clinic, skin testing showed a positive reaction to Gelofusin.
Case 3
A 57-year-old male with a background history of non-alcoholic hepatic cirrhosis and chronic obstructive respiratory disease presented for a mesocaval shunt. He had had a splenectomy and a splenocaval shunt two weeks prior to this operation. This previous procedure had been accompanied by marked blood loss and he had been resuscitated with crystalloid, colloid and blood and had required inotropes intraoperatively. His usual medications included omeprazole, flixotide and salbutamol. He had no known allergies. Preoperative blood tests are shown in Table 1 .
Premedication consisted of omeprazole and a salbutamol nebulizer. Anaesthesia was induced with midazolam, propofol, fentanyl and atracurium. A metaraminol infusion was commenced half an hour after induction to maintain the mean arterial pressure at about 80 mmHg. Ninety minutes after commencing the operation, during the infusion of a 500ml bag of Gelofusin, the patient became hypotensive (60/ 35 mmHg) and tachycardic (115/min). Increasing the metaraminol infusion had no effect. Widespread erythema was noted but there was no evidence of bronchospasm. Anaphylaxis was diagnosed and adrenaline boluses were given to a total of 1 mg. The patient also received a litre of 10% pentastarch solution (Hemohes ® : Braun, Auckland) and hydrocortisone. A noradrenaline infusion was commenced (500 µg/h) and was weaned near the end of the case. Blood was taken for full blood count, coagulation and tryptase and TEG ( Table 1 ). The TEG showed severe fibrinolysis and tranexamic acid 500 mg was given. A follow up TEG was not performed. Surgery and postoperative recovery were uneventful. Six weeks later at our Allergy Clinic, skin testing showed a positive reaction to Gelofusin.
Case 4
A 44-year-old male presented for orthotopic liver transplant for hepatocellular carcinoma. He had no other significant medical problems, was on no regular medications and had no history of drug allergy. Preoperative blood tests are shown in Table 1 .
Anaesthesia was induced with midazolam, propofol, suxamethonium and remifentanil and was maintained with desflurane in 50% oxygen and a remifentanil infusion. Atracurium 50 mg was also given. Twenty minutes after induction, the blood pressure began to drift downwards, with no response to metaraminol (1 mg, 1 mg, 1 mg) or a fluid bolus of Gelofusin ® . There was no evidence of bronchospasm. Widespread piloerection was noted. Anaphylaxis was diagnosed and adrenaline boluses were given (100 µg, 200 µg, 300 µg) and methylprednisone 1g. The patient received a total of three litres of crystalloid solution and 500 ml of Gelofusin ® . Blood was taken for full blood count, coagulation, tryptase concentration and TEG ( Table 1 ). The TEG showed severe fibrinolysis and tranexamic acid 1.0 g was given. The TEG was repeated, showing complete resolution of the coagulopathy ( Table 1 ). The blood pressure was supported with an adrenaline infusion (0.15 µg/kg/min) and surgery was continued in view of the hepatocellular carcinoma being just resectable. The rest of surgery proceeded uneventfully.
Six weeks later the patient was tested for all anaesthetic drugs, including muscle relaxants. He was also tested for allergy to chlorhexidine, penicillin and latex. No substance tested positive. The patient was not tested for allergy to Gelofusin ® as he did not receive any prior to the anaphylactic reaction.
DISCUSSION
Anaphylaxis is an immediate hypersensitivity reaction, produced by immunologically mediated release of physiologically active substances from mast cells (MCs) and basophils. It is characterized by a generalized response involving the cutaneous, cardiovascular and respiratory systems and although haemostatic changes may occur, they are often not investigated 2, 3 .
Although anaphylactoid reactions are identical clinically, the causative mechanism does not involve IgE and prior sensitization is not required 4, 5 . Increased mast cell tryptase (MCT) concentrations favour an IgE-mediated reaction but do not always distinguish between an anaphylactoid and anaphylactic reactions and therefore skin testing, which determines that the causative substance is an allergen, may be required 3, 6, 7 . Normally the concentration of circulating mast cell tryptase is close to or at zero, and serum needs to be taken one to six hours after the onset of a reaction to determine a rise in mast cell tryptase 7, 8 . Concentrations increase to a maximum approximately one hour after anaphylaxis and then fall with a half-life of about two hours. A tryptase level of >10 µg/l is regarded to be indicative of anaphylaxis. As tryptase-negative anaphylaxis can occur due to release of anaphylactic mediators from basophils rather than mast cells, without skin testing it is not possible to differentiate between an anaphylactoid and an anaphylactic reaction, as in Case 1.
Clot formation and breakdown and the effect anaphylaxis is thought to have on these processes are depicted diagrammatically in Figure 3 . Activation of the intrinsic coagulation pathway may cause disseminated intravascular coagulation and depletion of clotting factors 3 . Mast cell degranulation and the properties of the endothelium itself also contribute to 582 R. L. DE the coagulopathy seen. The fibrinolytic system comprises an inactive proenzyme, plasminogen, which can be converted to the active enzyme, plasmin. Plasmin degrades fibrin into soluble fibrin degradation products by two physiological plasminogen activators (PAs), tissue type PAs (tPA) and urokinase type PAs (uPA). Inhibition of the fibrinolytic system may occur either at the level of the plasminogen activators, by specific plasminogen activator inhibitors (PAIs) or at the level of plasmin by alpha 2 antiplasmin 9 . The profibrinolytic potential of a cell is determined by its capacity to produce and release plasminogen activators and plasminogen activator inhibitors 10 .
The mast cell plays a pivotal role in anaphylaxis and subsequent fibrinolysis. Mast cells are multipotent effector cells of the immune system, which usually reside in connective tissues in almost all organ systems. They are located around capillary vessels and in sentinel regions in order to respond to noxious stimuli. The immediate response from mast cells may be responsible for vasodilation, endothelial activation and leucocyte recruitment 11 . Mast cells store a number of active mediators: heparin, histamine, lipid products, chemokines, cytokines and the proteolytic enzymes chymase and tryptase which are released in response to certain stimuli, such as crosslinking of the IgE-receptor which occurs during anaphylaxis 10, 11 .
Tryptase is a glycosylated trypsin-like enzyme that is stored and released from all human mast cells. It is involved in cleaving four human proteins: fibrinogen, kininogen, vitronectin and pro-urokinase 12 . The cleavage of fibrinogen slows the process of coagulation and the cleavage of high molecular weight kininogen results in a reduction in the ability of this protein to stimulate coagulation via activation of Factor Xll 11 . It is also possible that tryptase may degrade procoagulant proteins and may prevent deposition of fibrin and act as an extra vascular anticoagulant 8 . Another possible mechanism is that, by activating urokinase, tryptase may accelerate fibrin lysis 8, 13 . Chymase contributes to fibrinolysis by inactivating thrombin 10 . Fibrinogenolysis by tryptase complements other mast cell mediators with anticoagulant properties such as proteases and also heparin, which acts as a cofactor of antithrombin III and tPA 10, 11, 14 . However there is little evidence that the heparin released from mast cells has an anticoagulant effect in vivo 11 .
The key enzyme of fibrinolysis, plasmin, is derived from its inactive progenitor plasminogen through catalytic action of plasminogen activators. In most cell systems, however, plasminogen activators are neutralized by plasminogen activator inhibitors.
Immunohistochemical staining experiments have shown that human tissue mast cells constitutively produce, express and release tissue type plasminogen activators in the absence of inhibitory plasminogen activator inhibitors 13, 14 . This would suggest that mast cells are profibrinolytic and are important in endogenous fibrinolysis, a repair function of this cell 10, 13, 15 . However there is more recent evidence that plasminogen activator inhibitors are produced by mast cells and this would temper their profibrinolytic tendency 11 .
Mast cells also express the receptor for urokinase type plasminogen activators 15 . Expression of urokinase receptors on mast cells may have implications for mast cell dependent microvascular processes associated with fibrinolysis, migration or local tissue repair 16 . Endothelial cells regulate vascular permeability and tone and play a major role in the regulation of the fibrinolytic and coagulation systems 17 . Mast cell degranulation products such as histamine and tryptase may stimulate endothelial cells directly.
In patients who have an anaphylactic reaction after an insect sting challenge, there is a rapid and substantial activation of plasminogen in plasma, which then leads to fibrinolysis. It has been suggested that the increase in plasminogen is due to an increase in tissue type plasminogen activator, which is released by the endothelium 17 . This is seen in response to hypoxemia, acidosis, and circulating (nor-) adrenaline and may also be initiated by mediators released by mast cells.
Haemostasis is a dynamic process and the static end-points that laboratory coagulation tests measure do not provide information regarding clot quality or the dynamics of its formation. These tests are also generally performed on centrifuged plasma fractions and only examine isolated portions of the coagulation cascade. In contrast, thrombelastography examines the interaction between platelets and the coagulation cascade. It is basically a modified whole blood clotting time and provides on-site analysis of global coagulation, including platelet function and fibrinolysis 18 . This information is usually available more rapidly than laboratory coagulation results, which is crucial for patients whose haemostatic functions are variable or rapidly changeable. The thrombelastography is a sensitive test for fibrinolysis or disseminated intravascular coagulation 19 . The thrombelastograph shown in Figure 1 is indicative of fibrinolysis, despite there being no clinical signs of increased bleeding. The early detection of fibrinolysis in the surgical setting is clearly an advantage, which enables institution of appropriate management and potentially reduced patient morbidity. Monitoring the effectiveness of antifibrinolytic therapy is another advantage of thrombelastography and is demonstrated in Figure 2 . In the above cases, the presence of fibrinolysis was determined soon after the patients' haemodynamic compromise using the thrombelastograph. The laboratory coagulation tests lagged behind the clinical situation and tranexamic acid had been given for the fibrinolysis seen on thrombelastography before the initial laboratory results were even processed.
The reduced maximal amplitude in Case 2 during the anaphylactic episode cannot be attributed to the patient's platelet count which was normal preoperatively at 238x10 9 .l -1 . Unfortunately platelet and fibrinogen levels were not performed at the time of anaphylaxis. Prolonged coagulation time (such as that in Case 2) can occur in fibrinolysis. Here we attribute it to fibrinolysis as there is no documentation of other factors such as clamping of portal venous inflow to the liver during resection in this case. 585 
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Anaesthesia and Intensive Care, Vol. 32, No. 4, August 2004 FIGURE 3: Coagulation, fibrinolysis and the effect of anaphylaxis on these processes. Note each arrow represents the activation and amplification of the subsequent factor. Mast cell degranulation causes release of a number of mediators: (1) Heparin is a cofactor for Antithrombin III which inhibits Factor Xa and Thrombin (2) Chymase inhibits thrombin (3) Tryptase cleaves fibrinogen thus slowing coagulation (4) Tryptase causes activation of uPA causing plasminogen to form plasmin (5) tPA causes plasminogen to form plasmin (6) tPA and uPA are unchecked as mast cells may not produce PAIs. Tryptase and histamine also stimulate the endothelium thereby causing an increase in vascular permeability, a reduction in vascular tone and further secretion of tPA.
Although the low estimate percentage lysis in Case 3 is not characteristic of fibrinolysis and blood clot lysis index were not performed, the overall thrombelastographic profile was suggestive of fibrinolysis.
It would be beneficial to conduct further laboratory tests for fibrinolysis and its correction post tranexamic acid, with D-dimers and euglobulin clot lysis time. However, these were not carried out in the cases reported here.
The global non-specific nature of the thrombelastograph is both an advantage and a disadvantage. The limitations of the thrombelastograph are therefore its inability to diagnose a specific haemostatic lesion and to consistently detect benefits of fractionated blood therapy. More scientific evidence is required in the form of appropriately powered clinical trials 20 .
Tranexamic acid was used in these cases and reversed the fibrinolysis seen on thrombelastography. The doses used ranged from 200 mg to 1.0 g (manufacturer's recommendation is 10 mg/kg). This synthetic antifibrinolytic drug forms a reversible complex with plasminogen and at higher concentrations, an irreversible complex with the active protease plasmin 21 . In the setting of an acute anaphylactic reaction, tranexamic acid may competitively reverse the effects of plasminogen activators which are unstable in circulating blood and diffuse into thrombus to cleave plasminogen to release plasmin 22 . The half-life of the terminal elimination phase of tranexamic acid is two hours as is the half-life of tryptase. This may have treatment implications for the expected time frame for fibrinolysis and the dose of tranexamic acid required if the tryptase level is known. It is possible that the coagulopathy seen after an anaphylactic reaction may be transient and that the tranexamic acid had little to do with its reversal. However anecdotal experience suggests that the coagulopathy can be quite sustained after an anaphylactic reaction. It is also possible that inappropriate or unnecessary use of tranexamic acid may cause potential harm if a prothrombotic state was induced during potential organ hypoperfusion seen during anaphylaxis. Nevertheless, early detection of the coagulopathy and its effective treatment with tranexamic acid reduced the morbidity of these patients. In the absence of clinical guidelines, it was not clear what the correct dose should be, but even the smallest dose given in this series, 200 mg, reversed the observed coagulopathy.
In conclusion, these cases illustrate anaphylactic or anaphylactoid reactions that occurred soon after induction or while surgery was in progress. The clinical significance of these reactions occurring after surgery has commenced is clear, as in addition to the more obvious cardiovascular, respiratory and cutaneous signs, haemostasis may also be compromised. Thrombelastography proved to be valuable for both rapidly identifying fibrinolysis and monitoring its correction. Tranexamic acid rapidly reversed the coagulopathy in these cases.
